Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 12:32 AM
Ignite Modification Date: 2025-12-25 @ 10:40 PM
NCT ID: NCT02147067
Description: The study investigators will record adverse effects, whether anticipated or unanticipated. All adverse events will be captured on an adverse event case report form and tracked from time of study enrollment until completion of all study follow-up (12 weeks).
Frequency Threshold: 0
Time Frame: Adverse events were collected from the time of study enrollment until completion of follow-up (12 weeks)
Study: NCT02147067
Study Brief: Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Ranolazine Participants receiving 500mg twice a day for 2 weeks then 1000mg twice daily of ranolazine for 10 weeks 0 None 0 11 0 11 View
Placebo Participants receiving a placebo to match the ranolazine dose for 12 weeks 0 None 0 11 0 11 View
Serious Events(If Any):
Other Events(If Any):